Silica Nanoparticles Coencapsulating Gadolinium Oxide and Horseradish Peroxidase for Imaging and Therapeutic Applications.

Silica nanoparticles coencapsulating gadolinium oxide and horseradish peroxidase for imaging and therapeutic applications.

Filed under: Drug and Alcohol Rehabilitation

Int J Nanomedicine. 2012; 7: 5491-500
Gupta N, Shrivastava A, Sharma RK

Mesoporous silica nanoparticles coencapsulating gadolinium oxide and horseradish peroxidase (HRP) have been synthesized in the aqueous core of sodium bis-(2-ethylhexyl) sulfosuccinate (AOT)-hexane-water reverse micelle. The average diameter of these silica particles is around 25 nm and the particles are spherical and highly monodispersed as depicted using transmission electron microscopy. The entrapment efficiency of HRP was found to be as high as 95%. Practically, the entrapped enzyme shows zero leachability up to 90 days. The enzyme entrapped in these silica nanoparticles follows Michaelis-Menten kinetics. Peroxidase entrapped in silica nanoparticles shows higher stability towards temperature and pH change as compared to free enzymes. The gadolinium oxide-doped silica nanoparticles are paramagnetic as observed from the nuclear magnetic resonance line-broadening effect on the proton spectrum of the surrounding water molecule. The entrapped enzyme, HRP, has been used to convert a benign prodrug, indole-3-acetic acid (IAA), to a toxic oxidized product and its toxic effect has been tested on cancerous cell lines through thiazolyl blue tetrazolium blue (MTT) assay. In vitro studies on different cancerous cell lines show that the enzyme has been entrapped and retains its activity inside the silica nanoparticles. IAA alone has no cytotoxic effect and it becomes active only after oxidative decarboxylation by HRP.
HubMed – drug


Typical coronary artery aneurysm exactly within drug-eluting stent implantation region in a patient with rheumatoid arthritis.

Filed under: Drug and Alcohol Rehabilitation

J Cardiovasc Dis Res. 2012 Oct; 3(4): 329-31
Zheng Y, Mao JY

The information presented comes from a case report concerning a left anterior descending coronary artery aneurysm (CAA). The typical “zig-zag” phenomenon, developed exactly within the segment of the sirolimus-eluting stent (SES), and in the left anterior descending coronary artery (LAD). The patient had a previous history of rheumatoid arthritis. We speculated that the CAA could be related to the vascular inflammatory reaction caused by the rheumatoid arthritis and the drug-eluting stent implantation.
HubMed – drug


Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin.

Filed under: Drug and Alcohol Rehabilitation

J Cardiovasc Dis Res. 2012 Oct; 3(4): 319-22
Alreja G, Inayatullah S, Goel S, Braden G

Rhabdomyolysis is an uncommon but life-threatening adverse effect of simvastatin therapy. A 73-year-old male on chronic simvastatin therapy received azithromycin for acute bronchitis. He presented with weakness of all extremities with a significant increase in creatinine phosphokinase levels and acute kidney injury. Simvastatin was stopped and supportive therapy with intravenous saline and bicarbonate was initiated. The serum creatinine and creatine phosphokinase returned to baseline in the next 7 days. Two months later, simvastatin was resumed without any recurrence of symptoms. Our case report highlights the rare description of rhabdomyolysis caused by a drug interaction between simvastatin with azithromycin.
HubMed – drug


Related Drug And Alcohol Rehabilitation Information…